|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu S, Bie ZX, Li YM, Li B, Kong FL, Peng
JZ and Li XG: Drug-eluting bead bronchial arterial
chemoembolization with and without microwave ablation for the
treatment of advanced and standard treatment-refractory/ineligible
non-small cell lung cancer: A comparative study. Front Oncol.
12:8518302022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wong KM, King GG and Harris WP: The
treatment landscape of advanced hepatocellular carcinoma. Curr
Oncol Rep. 24:917–927. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ni JY, Liu SS, Sun HL, Wang WD, Zhong ZL,
Hou SN, Chen YT and Xu LF: Transcatheter hepatic arterial infusion
chemotherapy vs sorafenib in the treatment of patients with
hepatocellular carcinoma of Barcelona Clinic Liver Cancer stage C:
A meta-analysis of Asian population. Onco Targets Ther.
11:7883–7894. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moriguchi M, Aramaki T, Nishiofuku H, Sato
R, Asakura K, Yamaguchi K, Tanaka T, Endo M and Itoh Y: Sorafenib
versus hepatic arterial infusion chemotherapy as initial treatment
for hepatocellular carcinoma with advanced portal vein tumor
thrombosis. Liver Cancer. 6:275–286. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Benson AB, D'Angelica MI, Abbott DE, Anaya
DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, et
al: Hepatobiliary cancers, version 2.2021, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 19:541–565. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lyu N, Wang X, Li JB, Lai JF, Chen QF, Li
SL, Deng HJ, He M, Mu LW and Zhao M: Arterial chemotherapy of
oxaliplatin plus fluorouracil versus sorafenib in advanced
hepatocellular carcinoma: A biomolecular exploratory, randomized,
phase III trial (FOHAIC-1). J Clin Oncol. 40:468–480. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kudo M, Matsui O, Izumi N, Iijima H,
Kadoya M, Imai Y, Okusaka T, Miyayama S, Tsuchiya K, Ueshima K, et
al: JSH consensus-based clinical practice guidelines for the
management of hepatocellular carcinoma: 2014 update by the liver
cancer study Group of Japan. Liver Cancer. 3:458–468. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cai Z, He C, Zhao C and Lin X: Survival
comparisons of hepatic arterial infusion chemotherapy with mFOLFOX
and transarterial chemoembolization in patients with unresectable
intrahepatic cholangiocarcinoma. Front Oncol. 11:6111182021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tsai WL, Lai KH, Liang HL, Hsu PI, Chan
HH, Chen WC, Yu HC, Tsay FW, Wang HM, Tsai HC and Cheng JS: Hepatic
arterial infusion chemotherapy for patients with huge unresectable
hepatocellular carcinoma. PLoS One. 9:e927842014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song DS, Song MJ, Bae SH, Chung WJ, Jang
JY, Kim YS, Lee SH, Park JY, Yim HJ, Cho SB, et al: A comparative
study between sorafenib and hepatic arterial infusion chemotherapy
for advanced hepatocellular carcinoma with portal vein tumor
thrombosis. J Gastroenterol. 50:445–454. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Regmi P, Hu HJ, Lv TR, Paudyal A, Sah RB,
Ma WJ, Jin YW and Li FY: Efficacy and safety of sorafenib plus
hepatic arterial infusion chemotherapy for advanced hepatocellular
carcinoma. Surg Oncol. 39:1016632021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li D, Pang Y, Xu L and Xu X: Efficacy and
safety of sorafenib combined with TACE in the treatment of advanced
hepatocellular carcinoma: A meta-analysis. J BUON. 26:1355–1364.
2021.PubMed/NCBI
|
|
14
|
Li QJ, He MK, Chen HW, Fang WQ, Zhou YM,
Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, et al: Hepatic arterial
infusion of oxaliplatin, fluorouracil, and leucovorin versus
transarterial chemoembolization for large hepatocellular carcinoma:
A randomized phase III trial. J Clin Oncol. 40:150–160. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai YS and Wu H: Is FOLFOX-HAIC superior
to transarterial chemoembolization in treating large hepatocellular
carcinoma? Hepatobiliary Surg Nutr. 11:164–165. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mei J, Yu H, Qin L and Jia Z: FOLFOX-HAIC
for unresectable large hepatocellular carcinoma: The effectiveness
has yet to be determined. J Clin Oncol. 40:18412022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Panagopoulos A, Solou K, Tatani I,
Triantafyllopoulos IK, Lakoumentas J, Kouzelis A, Athanasiou V and
Kokkalis ZT: What is the optimal surgical treatment for Neer type
IIB (IIC) distal clavicle fractures? A systematic review and
meta-analysis. J Orthop Surg Res. 17:2152022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang Y and Zeng T: Response to: Practical
methods for incorporating summary time-to-event data into
meta-analysis. Trials. 14:3912013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cumpston M, Li T, Page MJ, Chandler J,
Welch VA, Higgins JP and Thomas J: Updated guidance for trusted
systematic reviews: A new edition of the Cochrane handbook for
systematic reviews of interventions. Cochrane Database Syst Rev.
10:ED0001422019.PubMed/NCBI
|
|
21
|
Zheng K, Zhu X, Fu S, Cao G, Li QW, Xu L,
Chen H, Wu D, Yang R, Wang K, et al: Sorafenib plus hepatic
arterial infusion chemotherapy versus sorafenib for hepatocellular
carcinoma with major portal vein tumor thrombosis: A randomized
trial. Radiology. 303:455–464. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He M, Li Q, Zou R, Shen J, Fang W, Tan G,
Zhou Y, Wu X, Xu L, Wei W, et al: Sorafenib plus hepatic arterial
infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib
alone for hepatocellular carcinoma with portal vein invasion: A
randomized clinical trial. JAMA Oncol. 5:953–960. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kondo M, Morimoto M, Kobayashi S, Ohkawa
S, Hidaka H, Nakazawa T, Aikata H, Hatanaka T, Takizawa D,
Matsunaga K, et al: Randomized, phase II trial of sequential
hepatic arterial infusion chemotherapy and sorafenib versus
sorafenib alone as initial therapy for advanced hepatocellular
carcinoma: SCOOP-2 trial. BMC Cancer. 19:9542019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kudo M, Ueshima K, Yokosuka O, Ogasawara
S, Obi S, Izumi N, Aikata H, Nagano H, Hatano E, Sasaki Y, et al:
Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial
infusion chemotherapy versus sorafenib alone in patients with
advanced hepatocellular carcinoma (SILIUS): A randomised, open
label, phase 3 trial. Lancet Gastroenterol Hepatol. 3:424–432.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ikeda M, Shimizu S, Sato T, Morimoto M,
Kojima Y, Inaba Y, Hagihara A, Kudo M, Nakamori S, Kaneko S, et al:
Sorafenib plus hepatic arterial infusion chemotherapy with
cisplatin versus sorafenib for advanced hepatocellular carcinoma:
Randomized phase II trial. Ann Oncol. 27:2090–2096. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Park JW, Kim YJ, Kim DY, Bae SH, Paik SW,
Lee YJ, Kim HY, Lee HC, Han SY, Cheong JY, et al: Sorafenib with or
without concurrent transarterial chemoembolization in patients with
advanced hepatocellular carcinoma: The phase III STAH trial. J
Hepatol. 70:684–691. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee WC, Hung HC, Lee JC, Wang YC, Cheng
CH, Wu TH, Lee CF, Wu TJ, Chou HS and Chan KM: Treatment strategy
of adding transcatheter arterial chemoembolization to sorafenib for
advanced stage hepatocellular carcinoma. Cancer Rep (Hoboken).
4:e12942021.PubMed/NCBI
|
|
28
|
Barili F, Parolari A, Kappetein PA and
Freemantle N: Statistical primer: Heterogeneity, random- or
fixed-effects model analyses? Interact Cardiovasc Thorac Surg.
27:317–321. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Theile D, Grebhardt S, Haefeli WE and
Weiss J: Involvement of drug transporters in the synergistic action
of FOLFOX combination chemotherapy. Biochem Pharmacol.
78:1366–1373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bruno PM, Liu Y, Park GY, Murai J, Koch
CE, Eisen TJ, Pritchard JR, Pommier Y, Lippard SJ and Hemann MT: A
subset of platinum-containing chemotherapeutic agents kills cells
by inducing ribosome biogenesis stress. Nat Med. 23:461–471. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tesniere A, Schlemmer F, Boige V, Kepp O,
Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault
L, et al: Immunogenic death of colon cancer cells treated with
oxaliplatin. Oncogene. 29:482–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He MK, Le Y, Li QJ, Yu ZS, Li SH, Wei W,
Guo RP and Shi M: Hepatic artery infusion chemotherapy using
mFOLFOX versus transarterial chemoembolization for massive
unresectable hepatocellular carcinoma: A prospective non-randomized
study. Chin J Cancer. 36:832017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lewandowski RJ, Geschwind JF, Liapi E and
Salem R: Transcatheter intraarterial therapies: Rationale and
overview. Radiology. 259:641–657. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ma SQ, Cao BR, Zhang H, Luo LP, Ren Y, Hu
T and Chen CM: The lack of Raf-1 kinase feedback regulation
enhances antiapoptosis in cancer cells. Oncogene. 36:2014–2022.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mizukoshi E, Yamashita T, Arai K,
Terashima T, Kitahara M, Nakagawa H, Iida N, Fushimi K and Kaneko
S: Myeloid-derived suppressor cells correlate with patient outcomes
in hepatic arterial infusion chemotherapy for hepatocellular
carcinoma. Cancer Immunol Immunother. 65:715–725. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pratama MY, Pascut D, Massi MN and
Tiribelli C: The role of microRNA in the resistance to treatment of
hepatocellular carcinoma. Ann Transl Med. 7:5772019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chao Y, Chung YH, Han G, Yoon JH, Yang J,
Wang J, Shao GL, Kim BI and Lee TY: The combination of
transcatheter arterial chemoembolization and sorafenib is well
tolerated and effective in Asian patients with hepatocellular
carcinoma: Final results of the START trial. Int J Cancer.
136:1458–1467. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zheng L, Guo CY, Chen CS, Xiao JC, Hu HT,
Cheng HT, Zong DW, Jiang L and Li HL: Sorafenib improves lipiodol
deposition in transarterial chemoembolization of Chinese patients
with hepatocellular carcinoma: A long-term, retrospective study.
Oncotarget. 8:97613–97622. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
He X, Guo X, Zhang H, Kong X, Yang F and
Zheng C: Mechanism of action and efficacy of LY2109761, a TGF-β
receptor inhibitor, targeting tumor microenvironment in liver
cancer after TACE. Oncotarget. 9:1130–1142. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lin W, Wang H, Zhong M, Yu S, Zhao S,
Liang S, Du J, Cheng B, Gu W and Ling C: Effect and molecular
mechanisms of jiedu recipe on hypoxia-induced angiogenesis after
transcatheter arterial chemoembolization in hepatocellular
carcinoma. Evid Based Complement Alternat Med.
2021:65293762021.PubMed/NCBI
|
|
41
|
Yang P, Zhou W, Li C, Zhang M, Jiang Y,
Jiang R, Ba H, Li C, Wang J, Yin B, et al: Kupffer-cell-expressed
transmembrane TNF-α is a major contributor to lipopolysaccharide
and D-galactosamine-induced liver injury. Cell Tissue Res.
363:371–383. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Chen LX, Zou SJ, Li D, Zhou JY, Cheng ZT,
Zhao J, Zhu YL, Kuang D and Zhu XH: Prostate-specific membrane
antigen expression in hepatocellular carcinoma, cholangiocarcinoma,
and liver cirrhosis. World J Gastroenterol. 26:7664–7678. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bloom S, Kemp W and Lubel J: Portal
hypertension: Pathophysiology, diagnosis and management. Internal
Med J. 45:16–26. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fuentes-Lacouture MC, Barrera-Garavito EC,
Gomez A and Mantilla W: Non-cirrhotic portal hypertension in a
patient with colonic carcinoma treated with oxaliplatin. J Med
Cases. 12:99–101. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K,
Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib
versus sorafenib in first-line treatment of patients with
unresectable hepatocellular carcinoma: A randomised phase 3
non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Ding X, Sun W, Li W, Shen Y, Guo X, Teng
Y, Liu X, Zheng L, Li W and Chen J: Transarterial chemoembolization
plus lenvatinib versus transarterial chemoembolization plus
sorafenib as first-line treatment for hepatocellular carcinoma with
portal vein tumor thrombus: A prospective randomized study. Cancer.
127:3782–3793. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bruix J, Qin S, Merle P, Granito A, Huang
YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al:
Regorafenib for patients with hepatocellular carcinoma who
progressed on sorafenib treatment (RESORCE): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Abou-Alfa GK, Meyer T, Cheng AL,
El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park
JW, et al: Cabozantinib in patients with advanced and progressing
hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miyayama S, Yamashiro M, Ikeda R,
Matsumoto J, Takeuchi K, Sakuragawa N, Ueda T, Sanada T, Notsumata
K and Terada T: Efficacy of superselective conventional
transarterial chemoembolization using guidance software for
hepatocellular carcinoma within three lesions smaller than 3 cm.
Cancers (Basel). 13:63702021. View Article : Google Scholar : PubMed/NCBI
|
